(Q37605886)

21 August 2017

1 reference

title

Tenofovir for the treatment of hepatitis B virus (English)

1 reference

21 August 2017

1 reference

1 reference

1 reference

2

Chloe L Thio

1 reference

21 August 2017

Alice M Jenh

1

1 reference

21 August 2017

Paul A Pham

series ordinal

3

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 October 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

29

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

1212-1227

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

21 August 2017

1 reference

Review article: current antiviral therapy of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Fate of extrahepatic human stem and precursor cells after transplantation into mouse livers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir disoproxil fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir disoproxil fumarate for the treatment of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Variant of hepatitis B virus with primary resistance to adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir therapy for lamivudine resistance following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Replacement of tenofovir with adefovir may result in reactivation of hepatitis B virus replication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Reactivation of viral replication after replacement of tenofovir by adefovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Severe metabolic acidosis and renal failure in an HIV-1 patient receiving tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.10.1212

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.10.1212

1 reference

21 August 2017

1 reference